TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection

PLoS Pathogens

Volumn 12, Issue 3, 2016, Pages

  Jayaraman, Pushpa ^a   Jacques, Miye K ^a   Zhu, Chen ^b   Steblenko, Katherine M ^a   Stowell, Britni L ^a   Madi, Asaf ^b   Anderson, Ana C ^b   Kuchroo, Vijay K ^b   Behar, Samuel M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD160 ANTIGEN; CD244 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; LYMPHOCYTE ACTIVATING 3 PROTEIN; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN MUCIN DOMAIN 3 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, MOUSE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; IL10 PROTEIN, MOUSE; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; INFECTION CONTROL; MONONUCLEAR CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; T LYMPHOCYTE; TUBERCULOSIS; ANIMAL; CELL DIFFERENTIATION; GENETICS; HUMAN; IMMUNITY; IMMUNOLOGY; METABOLISM;

ANIMALS; CELL DIFFERENTIATION; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNITY; INTERLEUKIN-10; INTERLEUKIN-2; MICE; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, VIRUS; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 84962381128     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005490     Document Type: Article

References (55)

1. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR, Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis. 2012;54(6):784–91. doi: 10.1093/cid/cir95122267721; PubMed Central PMCID: PMC3284215.
2. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK, Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends in immunology. 2011. doi: 10.1016/j.it.2011.05.00321697013.
3. Wherry EJ, Blattman JN, Murali-Krishna K, van der MR, Ahmed R, Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. The Journal of Virology. 2003;77(8):4911–27. 12663797
4. Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity. 2014;40(2):289–302. doi: 10.1016/j.immuni.2014.01.00524530057; PubMed Central PMCID: PMC3990591.
5. Wherry EJ, Ha S-J, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670–84. doi: 10.1016/j.immuni.2007.09.00617950003
6. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29–37. Epub 2008/12/02. doi: 10.1038/ni.167919043418; PubMed Central PMCID: PMC2605166.
7. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine. 2010;207(10):2187–94. doi: 10.1084/jem.2010064320819927
8. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res. 2014;74(4):1045–55. doi: 10.1158/0008-5472.CAN-13-290824343228; PubMed Central PMCID: PMC3952491.
9. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501–10. doi: 10.1182/blood-2010-10-31042521385853; PubMed Central PMCID: PMC3099570.
10. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245–52. doi: 10.1038/ni127116286920.
11. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102–10. doi: 10.1038/ni98814556006.
12. Jin H-T, Anderson AC, Tan WG, West EE, Ha S-J, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences. 2010;107(33):14733–8. doi: 10.1073/pnas.1009731107
13. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205(12):2763–79. doi: 10.1084/jem.2008139819001139.
14. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. The Journal of Virology. 2009;83(18):9122–30. doi: 10.1128/JVI.00639-0919587053
15. Ju Y, Hou N, Zhang XN, Zhao D, Liu Y, Wang JJ, et al. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell MolImmunol. 2009;6(1):35–43.
16. Dietze KK, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U, Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog. 2013;9(12):e1003798. doi: 10.1371/journal.ppat.100379824339778; PubMed Central PMCID: PMC3855586.
17. Wang X, Cao Z, Jiang J, Li Y, Dong M, Ostrowski M, et al. Elevated expression of Tim-3 on CD8 T cells correlates with disease severity of pulmonary tuberculosis. The Journal of infection. 2011;62(4):292–300. doi: 10.1016/j.jinf.2011.02.01321382414
18. Qiu Y, Chen J, Liao H, Zhang Y, Wang H, Li S, et al. Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions. PLoS pathogens. 2012;8(11):e1002984. papers2://publication/doi/10.1371/journal.ppat.1002984. doi: 10.1371/journal.ppat.100298423144609
19. Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, et al. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med. 2010;207(11):2343–54. doi: 10.1084/jem.2010068720937702.
20. Woodworth JS, Shin D, Volman M, Nunes-Alves C, Fortune SM, Behar SM, Mycobacterium tuberculosis directs immunofocusing of CD8+ T cell responses despite vaccination. J Immunol. 2011;186(3):1627–37. doi: 10.4049/jimmunol.100291121178003; PubMed Central PMCID: PMC3133636.
21. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29–37. doi: 10.1038/ni.167919043418; PubMed Central PMCID: PMC2605166.
22. Sakai S, Kauffman KD, Schenkel JM, McBerry CC, Mayer-Barber KD, Masopust D, et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J Immunol. 2014;192(7):2965–9. doi: 10.4049/jimmunol.140001924591367; PubMed Central PMCID: PMC4010124.
23. Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc. 2014;9(1):209–22. doi: 10.1038/nprot.2014.00524385150.
24. Cyktor JC, Carruthers B, Beamer GL, Turner J, Clonal expansions of CD8+ T cells with IL-10 secreting capacity occur during chronic Mycobacterium tuberculosis infection. PLoS ONE. 2013;8(3):e58612. papers2://publication/doi/10.1371/journal.pone.0058612. doi: 10.1371/journal.pone.005861223472214
25. Doering TA, Crawford A, Angelosanto JM, Paley MA, Ziegler CG, Wherry EJ, Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity. 2012;37(6):1130–44. doi: 10.1016/j.immuni.2012.08.02123159438; PubMed Central PMCID: PMC3749234.
26. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682–7. doi: 10.1038/nature0444416382236.
27. Heng TS, Painter MW, Immunological Genome Project CThe Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol. 2008;9(10):1091–4. doi: 10.1038/ni1008-109118800157.
28. Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Moorman JP, et al. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol. 2012;91(2):189–96. doi: 10.1189/jlb.101059121844165; PubMed Central PMCID: PMCPMC3290426.
29. Kamath AB, Behar SM, Anamnestic responses of mice following Mycobacterium tuberculosis infection. Infect Immun. 2005;73(9):6110–8. doi: 10.1128/IAI.73.9.6110-6118.200516113332; PubMed Central PMCID: PMC1231147.
30. Kamath AB, Alt J, Debbabi H, Taylor C, Behar SM, The major histocompatibility complex haplotype affects T-cell recognition of mycobacterial antigens but not resistance to Mycobacterium tuberculosis in C3H mice. Infect Immun. 2004;72(12):6790–8. doi: 10.1128/IAI.72.12.6790-6798.200415557599; PubMed Central PMCID: PMC529145.
31. Kamath AB, Alt J, Debbabi H, Behar SM, Toll-Like Receptor 4-Defective C3H/HeJ Mice Are Not More Susceptible than Other C3H Substrains to Infection with Mycobacterium tuberculosis. Infection and Immunity. 2003;71(7):4112–8. doi: 10.1128/iai.71.7.4112-4118.200312819102
32. Wu W, Wu W, Shi Y, Shi Y, Li S, Li S, et al. Blockade of Tim-3 signaling restores the virus-specific CD8+ T-cell response in patients with chronic hepatitis B. European Journal of Immunology. 2012;42(5):1180–91. papers2://publication/doi/10.1002/eji.201141852. doi: 10.1002/eji.20114185222539292
33. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012;56(4):1342–51. doi: 10.1002/hep.2577722505239.
34. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. Journal of Experimental Medicine. 2010;207(10):2175–86. doi: 10.1084/jem.2010063720819923
35. Redford PS, Murray PJ, O'Garra A, The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol. 2011;4(3):261–70. doi: 10.1038/mi.2011.721451501.
36. Larson RP, Shafiani S, Urdahl KB, Foxp3(+) regulatory T cells in tuberculosis. Adv Exp Med Biol. 2013;783:165–80. doi: 10.1007/978-1-4614-6111-1_923468109.
37. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I, Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol. 2009;174(6):2190–201. doi: 10.2353/ajpath.2009.08107519443700; PubMed Central PMCID: PMC2684184.
38. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, et al. TIM3FOXP3 regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(4):e23849. doi: 10.4161/onci.2384923734331; PubMed Central PMCID: PMC3654601.
39. Jayaraman P, Sada-Ovalle I, Nishimura T, Anderson AC, Kuchroo VK, Remold HG, et al. IL-1beta promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. J Immunol. 2013;190(8):4196–204. doi: 10.4049/jimmunol.120268823487424; PubMed Central PMCID: PMC3622150.
40. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH, Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006;203(10):2223–7. doi: 10.1084/jem.2006180017000870; PubMed Central PMCID: PMC2118103.
41. Bafica A, Scanga CA, Serhan C, Machado F, White S, Sher A, et al. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest. 2005;115(6):1601–6. doi: 10.1172/JCI2394915931391; PubMed Central PMCID: PMC1136995.
42. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141–3. doi: 10.1126/science.114853618006747.
43. Veenstra RG, Taylor PA, Zhou Q, Panoskaltsis-Mortari A, Hirashima M, Flynn R, et al. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood. 2012;120(3):682–90. doi: 10.1182/blood-2011-10-38797722677125; PubMed Central PMCID: PMCPMC3401220.
44. Gupta S, Thornley TB, Gao W, Larocca R, Turka LA, Kuchroo VK, et al. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J Clin Invest. 2012;122(7):2395–404. doi: 10.1172/JCI4513822684103; PubMed Central PMCID: PMCPMC3386804.
45. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–72. 8671665.
46. Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386–90. doi: 10.1038/nature1384825363763; PubMed Central PMCID: PMC4297519.
47. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12):1212–8. 24240160
48. Nishimura H, Nose M, Hiai H, Minato N, Honjo T, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51. 10485649.
49. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319–22. doi: 10.1126/science.291.5502.31911209085.
50. Kawamoto S, Tran TH, Maruya M, Suzuki K, Doi Y, Tsutsui Y, et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science. 2012;336(6080):485–9. doi: 10.1126/science.121771822539724.
51. Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A, CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol. 2011;186(3):1598–607. doi: 10.4049/jimmunol.100330421172867.
52. Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A. 2010;107(30):13402–7. doi: 10.1073/pnas.100739410720624978; PubMed Central PMCID: PMC2922129.
53. Topalian SL, Drake CG, Pardoll DM, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–12. doi: 10.1016/j.coi.2011.12.00922236695; PubMed Central PMCID: PMC3319479.
54. Speck S, Lim J, Shelake S, Matka M, Stoddard J, Farr A, et al. TGF-beta signaling initiated in dendritic cells instructs suppressive effects on Th17 differentiation at the site of neuroinflammation. PLoS One. 2014;9(7):e102390. doi: 10.1371/journal.pone.010239025072375; PubMed Central PMCID: PMC4114567.
55. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP, GenePattern 2.0. Nature genetics. 2006;38(5):500–1. Epub 2006/04/28. doi: 10.1038/ng0506-50016642009.